New synthesis routes for drugs

PLASMIA is a biotechnology company dedicated to researching new and more efficient synthesis methods for different types of drugs.

The technology, patented by PLASMIA, is based on the use of enzymes that catalyze the synthesis reactions of nucleoside analogues in a single step. Obtaining nucleoside analogues with this technology represents a faster synthesis , a reduction in costs and a lower production of waste , decreasing its economic and environmental impact.

Currently, PLASMIA is working on the development of synthesis pathways based on the use of a wide variety of enzymes to improve the production of different types of Active Ingredients (APIs) in the oncology and antiviral fields , in different stages of development ranging from Proof of Concept to industrial piloting.

PLASMIA technology can also be used in different stages of the Drug Discovery process , either in the production of libraries of new molecules or in the modification of these molecules to obtain compounds with greater biological activity (Hit to Lead campaign and Lead Optimization).